Group 1 - The core point of the article is the announcement by *ST Lvkang regarding its board meeting and the composition of its revenue for the first half of 2025 [1] - The board meeting was held on December 8, 2025, to discuss the proposal for the temporary shareholders' meeting [1] - The revenue composition for *ST Lvkang in the first half of 2025 is as follows: veterinary medicine 61.79%, photovoltaic film 26.1%, biopesticides 5.99%, others 2.83%, and food additives 2.19% [1] Group 2 - As of the report, *ST Lvkang has a market capitalization of 5.7 billion yuan [1]

Core Viewpoint - The company has obtained a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting Newcastle disease, avian influenza (H9 subtype), and avian adenovirus disease (I group 4) [1] Group 1: Regulatory Compliance - The vaccine registration is in accordance with the Veterinary Drug Management Regulations and the Measures for the Approval Number Management of Veterinary Drug Products [1] - The company is currently in the process of applying for the veterinary product approval number issued by the Ministry of Agriculture and Rural Affairs, which is required before the product can be marketed [1]

Core Viewpoint - Reap Bio announced the convening of its fifth board meeting to discuss amendments to the company's articles of association, indicating ongoing governance and strategic adjustments [1] Company Summary - Reap Bio's revenue composition for the year 2024 is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report, Reap Bio has a market capitalization of 9.2 billion yuan [1]

Core Viewpoint - Green Kang Biochemical has completed the transfer of its controlling shareholder from Shanghai Kangyi to Zongteng Network, alongside the divestiture of its photovoltaic assets, amidst ongoing financial struggles and operational challenges in its core veterinary medicine business [1][3]. Group 1: Company Background and Financial Struggles - Green Kang Biochemical, originally focused on veterinary drug R&D and production, has faced declining net profits since its IPO in 2017, culminating in significant losses starting in 2021 [1][2]. - The company reported a total loss of 789 million yuan from 2022 to 2024, with its net assets reaching -24.54 million yuan by the end of 2024, leading to a risk of delisting [3][4]. Group 2: Transition to Photovoltaic Business - The company attempted to pivot to the photovoltaic sector by acquiring Jiangxi Weike New Materials Technology Co., with a premium of 632%, but this transition resulted in substantial losses due to falling prices in the photovoltaic industry [2][3]. - The photovoltaic business accounted for approximately 36% of the company's revenue in 2024, but the overall revenue from the veterinary business remains critical, constituting 84% of the adjusted revenue [5][6]. Group 3: New Controlling Shareholder and Future Prospects - Zongteng Network, the new controlling shareholder, specializes in cross-border logistics and reported a revenue of 27.105 billion yuan and a net profit of 1.122 billion yuan in 2024, raising questions about its ability to turn around Green Kang Biochemical's fortunes [6]. - The veterinary business has shown volatility, with a gross margin of only 7.35% in 2024, although it improved to 21.61% in the first half of the year due to rising pig prices [5][6].

公司已按照《兽药管理条例》《兽药产品批准文号管理办法》等规定的要求取得硫糖铝片兽药产品批准 文号批件，该兽药具备生产上市销售条件。该兽药批准文号的取得可进一步丰富公司产品品类，对推动 宠物用药战略布局、促进公司发展具有积极意义。 子公司动保科技硫糖铝片用于治疗犬胃溃疡、十二指肠溃疡和胃炎。 格隆汇11月28日丨昂利康(002940.SZ)公布,近日，公司子公司浙江昂利康动保科技有限公司收到中华人 民共和国农业农村部核准签发的"硫糖铝片"兽药产品批准文号批件。通用名称：硫糖铝片兽药产品批准 文号，兽药字：111187075。 ...

Core Viewpoint - TianKang Biological announced the resignation of its general manager, Cheng Hui, due to approaching retirement age, while appointing Xu Heng as the new general manager [1] Company Summary - Cheng Hui's resignation was accepted by the board, and he will continue to serve as a director and a member of the Strategic and Investment Committee [1] - The company's revenue composition for the first half of 2025 is as follows: pig farming 32.2%, feed 27.51%, agricultural product processing 16.37%, corn storage 14.75%, and veterinary medicine 5.44% [1] - As of the report, TianKang Biological has a market capitalization of 9.8 billion yuan [1]

Core Viewpoint - The company, Blue Biological (603739), has received approval for its new veterinary drug "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, with the issuance of the "New Veterinary Drug Registration Certificate" [1] Group 1 - The company and its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., jointly applied for the approval of the new veterinary drug [1] - The approval signifies a significant milestone for the company in expanding its product offerings in the veterinary medicine sector [1]

Core Viewpoint - The company, Blue Biological (603739.SH), announced that its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., along with other units, has received approval for "Oxytetracycline Iodine Solution" as a Class III new veterinary drug, and has recently been issued a "New Veterinary Drug Registration Certificate" [1] Company Summary - Blue Biological has successfully obtained regulatory approval for a new veterinary drug, indicating progress in its product development pipeline [1] - The approval of the new veterinary drug may enhance the company's market position and expand its product offerings in the veterinary pharmaceutical sector [1] Industry Summary - The approval of new veterinary drugs is significant for the industry, as it reflects ongoing innovation and regulatory compliance within the veterinary pharmaceutical market [1] - The introduction of Class III new veterinary drugs can potentially lead to increased competition and improved animal health solutions in the market [1]

Core Viewpoint - *ST Lvkang (sz002868) experienced a trading halt on November 27, 2025, with a closing price of 46.06 yuan, marking a 4.99% increase, and a total market capitalization of 7.158 billion yuan, driven by asset restructuring, control change, and financial optimization [1] Group 1: Asset Restructuring - The company sold equity in three loss-making photovoltaic subsidiaries through a cash transaction on November 26, effectively shedding unprofitable assets and improving the quality of consolidated financial statements [1] - Following the asset sale, the company's debt-to-asset ratio significantly decreased, and it secured 150 million yuan in unsecured loans for daily operations, enhancing its financial condition [1] Group 2: Strategic Focus - Originally focused on veterinary drug research, production, and sales, the company has transitioned to a dual business model of "animal health products + photovoltaic film products" since 2023, but the photovoltaic segment was unprofitable [1] - The divestiture of the photovoltaic business allows the company to concentrate on its core operations, which have recently gained market attention, potentially benefiting from the sector's popularity [1] Group 3: Market Dynamics - On November 18, the company was included in the "Dragon and Tiger List," indicating participation from speculative funds, which may have contributed to the stock price increase despite foreign capital net selling on that day [1] - The series of favorable actions taken by the company is likely to attract market attention and drive stock price momentum [1]

Core Viewpoint - *ST绿康 has completed the transfer of control and the sale of its loss-making photovoltaic film business, which is expected to improve its future financial situation [1][2]. Group 1: Company Overview - *ST绿康, originally focused on veterinary pharmaceuticals and related products, attempted to diversify into the photovoltaic film sector through acquisitions in 2022, but this transition was unsuccessful [1]. - The company reported significant losses, with net profits of -122 million yuan in 2022, -222 million yuan in 2023, and projected -445 million yuan in 2024 [1]. Group 2: Control Transfer and Asset Sale - The original controlling shareholder, Shanghai Kangyi Investment Co., initiated the control transfer process in April 2023, culminating in the transfer to Fujian Zongteng Network Co. on November 25, 2023 [2]. - The asset sale involved the divestment of three subsidiaries related to the photovoltaic business at a price of 0 yuan, effectively removing the loss-making assets from the company's balance sheet [2]. Group 3: New Controlling Shareholder - The new controlling shareholder, Zongteng Network, established in 2009, specializes in global cross-border e-commerce infrastructure services, focusing on warehousing and logistics [3]. - For the fiscal year 2024, Zongteng Network reported total revenue of 27.105 billion yuan and a net profit of 1.122 billion yuan, with total assets of 10.443 billion yuan and total liabilities of 4.8 billion yuan [3].